Core Viewpoint - The company has shown improvement in financial performance, expanding its business scale, deepening the application of digital platforms, and experiencing a clear trend of industry concentration, attracting institutional attention [1]. Financial Performance - For the first three quarters of 2025, the company reported revenue of 609 million, a year-on-year increase of 2.59%, and a net profit attributable to shareholders of 87.38 million, up 20.92%. In the third quarter alone, revenue reached 219 million, reflecting a year-on-year growth of 9.84%, while net profit surged by 91.6% to 33.23 million, with a gross margin increase to 25.58% [2]. Business Development - As of the end of September 2025, the company has undertaken over 4,200 international and domestic SMO projects, with 2,538 projects currently in execution. The service scope includes the top ten global pharmaceutical companies in 2024, such as Merck and AstraZeneca, indicating a quarterly growth trend in project numbers and demonstrating business resilience [3]. Technological Advancements - The company has developed its own platform, the "Rui Xing" intelligent management system, which integrates AI functionalities to enhance the efficiency of clinical trials. Investor relations activities in 2025 indicated that this platform has achieved data visualization and intelligent management, contributing to improved service quality [4]. Industry Environment - According to investor activities in February 2026, resources in the SMO industry are gradually concentrating towards leading enterprises. As a leading company, the firm benefits from regulatory policy support and accumulated customer resources, optimizing the competitive landscape of the industry [5]. Institutional Interest - In January 2026, the company hosted discussions with several institutions, including Huatai PineBridge Fund, focusing on business strategy and quality management systems. Over the past year, the company has received a total of 210 institutional visits, reflecting a high level of market interest [6].